Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Allan Lipton

Showing results (71-80 of 148) with videos related to

Pageof 15
Sort By:
Clinical Advances in Hematology & Oncology : H&O|September 11, 2009
New opportunities for the management of cancer-related bone complicationsAllan Lipton, Gordon A Brown, Gregory R Mundy, et al.
Clinical Chemistry|September 23, 2003
Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancerWalter P Carney, Rainer Neumann, Allan Lipton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2004
Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acidAllan Lipton, Alejandro Colombo-Berra, Ronald M Bukowski, et al.
Cancer Immunology, Immunotherapy : CII|July 3, 2007
A phase-I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumorsMatthew G Fury, Allan Lipton, Katherine M Smith, et al.
Clinical Breast Cancer|July 13, 2004
Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancerWalter P Carney, Rainer Neumann, Allan Lipton, et al.
Cancer Treatment Reviews|June 27, 2008
Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directionsRobert Coleman, Janet Brown, Evangelos Terpos, et al.
Oncology Reports|January 5, 2007
Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitorLois M Witters, Amy Witkoski, Maricarmen D Planas-Silva, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|August 6, 2009
Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposureJean-Jacques Body, Allan Lipton, Julie Gralow, et al.
BMC Cancer|August 8, 2009
Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidityPierre P Major, Richard J Cook, Allan Lipton, et al.
Clinical Lymphoma & Myeloma|June 15, 2007
Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myelomaAllan Lipton, Richard J Cook, Robert E Coleman, et al.
Pageof 15

Showing results (71-80 of 148) with videos related to

Sort By:
Pageof 15
Clinical Advances in Hematology & Oncology : H&O|September 11, 2009
New opportunities for the management of cancer-related bone complicationsAllan Lipton, Gordon A Brown, Gregory R Mundy, et al.
Clinical Chemistry|September 23, 2003
Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancerWalter P Carney, Rainer Neumann, Allan Lipton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2004
Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acidAllan Lipton, Alejandro Colombo-Berra, Ronald M Bukowski, et al.
Cancer Immunology, Immunotherapy : CII|July 3, 2007
A phase-I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumorsMatthew G Fury, Allan Lipton, Katherine M Smith, et al.
Clinical Breast Cancer|July 13, 2004
Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancerWalter P Carney, Rainer Neumann, Allan Lipton, et al.
Cancer Treatment Reviews|June 27, 2008
Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directionsRobert Coleman, Janet Brown, Evangelos Terpos, et al.
Oncology Reports|January 5, 2007
Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitorLois M Witters, Amy Witkoski, Maricarmen D Planas-Silva, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|August 6, 2009
Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposureJean-Jacques Body, Allan Lipton, Julie Gralow, et al.
BMC Cancer|August 8, 2009
Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidityPierre P Major, Richard J Cook, Allan Lipton, et al.
Clinical Lymphoma & Myeloma|June 15, 2007
Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myelomaAllan Lipton, Richard J Cook, Robert E Coleman, et al.
Pageof 15